Effect of a Single Nights' Wake Followed by Bright Light Therapy for Severe Depression
Wake and Bright Light Therapy for Depression Among Admitted Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Västra Götaland
-
Gothenburg, Västra Götaland, Sweden
- Sahlgrenska University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Depressive episode requiring admission to a psychiatric hospital (including unipolar and bipolar depression).
Exclusion Criteria:
- Psychotic symptoms/agitation
- Compulsory admission
- Confusion
- Active substance use disorder
- Eye disease preventing bright light therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Chronobiological intervention
Single night's wake therapy followed by bright light therapy for a week as add-on treatment to treatment as usual.
|
Eligible patients are assisted in maintaining total sleep deprivation during one night
Other Names:
Bright light according to patients´ own circadian rhythm each morning for a week.
All patients are admitted due to severe depression and are under observation and most receive antidepressive medication and if necessary anxiolytic/antipsychotic medication.
Since all patients are admitted due to a severe mental illness, they will receive medication according to indication.
Most patients have already tried more than one antidepressant at the time of admission.
In cases of severe anxiety, anxiolytics are prescribed but this is kept to a minimum.
|
|
Active Comparator: Control
Treatment as usual including a private educational meeting in sleep hygiene.
|
All patients are admitted due to severe depression and are under observation and most receive antidepressive medication and if necessary anxiolytic/antipsychotic medication.
Since all patients are admitted due to a severe mental illness, they will receive medication according to indication.
Most patients have already tried more than one antidepressant at the time of admission.
In cases of severe anxiety, anxiolytics are prescribed but this is kept to a minimum.
A short sleep hygiene consultation.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
MADRS-S score reduction of 50%
Time Frame: One week
|
Montgomery Asberg Depression Rating Scale
|
One week
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
MADRS-S score at discharge
Time Frame: Participants will be followed at discharge, an expected average of 2-3 weeks
|
Montgomery Asberg Depression Rating Scale
|
Participants will be followed at discharge, an expected average of 2-3 weeks
|
|
MADRS-S score at follow-up
Time Frame: 10-14 weeks
|
Montgomery Asberg Depression Rating Scale
|
10-14 weeks
|
|
ISI score score at discharge
Time Frame: Participants will be followed at discharge, an expected average of 2-3 weeks
|
Insomnia Severity Index - Self administered scale of sleep quality
|
Participants will be followed at discharge, an expected average of 2-3 weeks
|
|
ISI score score at follow-up
Time Frame: 10-14 weeks
|
Insomnia Severity Index - Self administered scale of sleep quality
|
10-14 weeks
|
|
ISI score reduction of 50%
Time Frame: One week
|
Insomnia Severity Index - Self administered scale of sleep quality
|
One week
|
|
Length of stay
Time Frame: The number of days between admission and discharge
|
Patients will be followed up 10-14 weeks after discharge and the total number of days in inpatient services calculated.
|
The number of days between admission and discharge
|
|
Re-admission
Time Frame: 10-14 weeks
|
10-14 weeks
|
|
|
CGI score
Time Frame: One week
|
Clinical global impression
|
One week
|
|
CGI score
Time Frame: 10-14 weeks
|
Clinical global impression
|
10-14 weeks
|
|
Medication use
Time Frame: 10-14 weeks
|
The use of antidepressants, anxiolytics or other psychiatric medication will be registered at follow-up.
The number of patients using more than one medication and the dosage will be compared.
|
10-14 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Steinn Steingrimsson, MD, PhD, Sahlgrenska University Hospital, Sweden
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CB001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
NCT07082998RecruitingDepression | Depression - Major Depressive Disorder | Depression Chronic | Depression in Adults | Depression Disorders | Depression Disorder
-
NCT05267340Active, not recruitingDepression Moderate | Depression Mild | Depression, Teen
-
NCT04211467WithdrawnDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression Chronic
-
NCT07617467RecruitingAnxiety | Anxiety Depression | Depression Anxiety Disorder | Depression - Major Depressive Disorder
-
NCT04504175CompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant Depression
-
NCT06979544CompletedDepression, Postpartum | Postnatal Depression | Peripartum Depression | Depression, Post-Partum | Postpartum Depression (PPD) | Post-Natal Depression
-
NCT06374056Active, not recruitingDepression | Depression Moderate | Depression Severe | Depression Mild
-
NCT06809907RecruitingDepression | Depression Moderate | Depression Severe | Depression Mild
-
NCT07464886Recruiting
-
NCT07416747Not yet recruitingDepression | Depression in Adults | Depression Disorder
Clinical Trials on Single night's wake therapy
-
NCT02047968Completed
-
NCT03405493CompletedDepression | Depressive Disorder, Major | Depression, Unipolar | Depression Moderate
-
NCT04213638Unknown
-
NCT06552325Not yet recruitingHiv | Substance Use | Mental Health Issue
-
NCT07496281Not yet recruitingCoronary Artery Disease | Atrial Fibrillation (AF) | Drug-eluting Stent
-
NCT01717261Completed
-
NCT04049188Unknown
-
NCT07558005Not yet recruitingWellbeing | Stress | Mental Health | Psychological | Trauma Exposure
-
NCT05217966Recruiting
-
NCT06924268Enrolling by invitationPain | Anxiety | Emotional Distress